Area of research
Endocrinology, Diabetes and Metabolism · Surgery
Research interest
Research interests include Diabetes Treatment and Management, Diabetes Management and Research, Pancreatic function and diabetes, and Neuroendocrine Tumor Research Advances.
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease
Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure
Efficacy and safety of sotagliflozin in patients with type <scp>2</scp> diabetes and severe renal impairment
Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome
Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program
Dose‐dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial
Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study
HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study
Efficacy of sotagliflozin 400 mg/day in 1402 patients with type 1 diabetes treated with any insulin regimen (inTandem 3)
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide